EGFR-mutant NSCLC—Osimertinib continues to be the CNS-active first-line standard; longitudinal cohorts will characterize the evolving patterns of brain involvement in 2024–2025, with improvements in intracranial responses and delayed CNS progression compared to earlier generation TKIs [29,30]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.